title: Sequential Inhalational Tobramycin-Colistin-Combination in CF-Patients with Chronic P. Aeruginosa Colonization - an Observational Study.
abstract: OBJECTIVE
  In cystic fibrosis (CF), chronic microbial lung infections are difficult to treat and cause morbidity and increased mortality.
  
  
  METHODS
  In a multicentre, open-label, exploratory, non-interventional study, inhaled tobramycin (300 mg twice daily) and colistin (1 million I.U. twice daily) were sequentially combined with the aim to investigate the effect on 41 CF patients with chronic P. aeruginosa infections for six months (mean age 24 ± 10.8y).
  
  
  RESULTS
  Six patients had adverse events that were assessed as being related to treatment. Mucus production and coughing both decreased in 39%, whereas FEV1 absolute and relative to baseline increased by 4.9% and 9.1%, respectively (p = 0.004) in 29 patients, who were definitely treated sequentially. Efficacy of the therapy was rated 'excellent' or 'good' by the physicians in 80.5% of the patients.
  
  
  CONCLUSIONS
  The results indicate that treatment with inhaled antibiotics, sequentially combined, was very well tolerated by most patients and may have a beneficial effect, even if transitory on lung function and respiratory symptoms.
authors: Department of Pediatrics, Comprehensive Cystic Fibrosis Center, University Children`s Hospital Tuebingen, Tuebingen, Germany.
authors: Joachim
authors: J
authors: Riethmüller
authors: Gloria
authors: G
authors: Herrmann
authors: Ute
authors: U
authors: Graepler-Mainka
authors: Dorothea
authors: D
authors: Hellwig
authors: Hans-Eberhard
authors: HE
authors: Heuer
authors: Susanne
authors: S
authors: Heyder
authors: Holger
authors: H
authors: Köster
authors: Birte
authors: B
authors: Kinder
authors: Kristina
authors: K
authors: Kröger
authors: Klaus
authors: K
authors: Paul
authors: Krystyna
authors: K
authors: Poplawska
authors: Volker O
authors: VO
authors: Melichar
authors: Christina
authors: C
authors: Smaczny
authors: Uwe
authors: U
authors: Mellies
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003091:Colistin / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development; D014031:Tobramycin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D014031:Tobramycin; D003091:Colistin